GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AngioLab Inc (XKRX:251280) » Definitions » Cash Flow from Others

AngioLab (XKRX:251280) Cash Flow from Others : ₩120.8 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is AngioLab Cash Flow from Others?

AngioLab's cash flow from others for the six months ended in Dec. 2023 was ₩120.8 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Dec. 2023 was ₩120.8 Mil.


AngioLab Cash Flow from Others Historical Data

The historical data trend for AngioLab's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioLab Cash Flow from Others Chart

AngioLab Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Others
Get a 7-Day Free Trial 5,143.83 -3,263.00 -223.90 -290.27 120.76

AngioLab Semi-Annual Data
Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Others Get a 7-Day Free Trial 5,143.83 -3,263.00 -223.90 -290.27 120.76

AngioLab Cash Flow from Others Calculation

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Others for the trailing twelve months (TTM) ended in Dec. 2023 was ₩120.8 Mil.

AngioLab Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of AngioLab's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


AngioLab (XKRX:251280) Business Description

Traded in Other Exchanges
N/A
Address
65 Techno 3ro, Suite 159, Hanshin S Mecca, Yuseong-gu, Doejeon, CHN
AngioLab Inc is a biotechnology company. It develops products based on angiogenesis inhibitors. It discovers, develops, and markets anti-angiogenic candidates to inhibit the abnormal growth of new blood vessel.

AngioLab (XKRX:251280) Headlines

No Headlines